Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
On March 12th, we organised the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts explored the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of the disease ...
On December 12th, we organised the webinar:Revolutionizing Kidney Failure Treatment: Clinical Impact and Lessons Learned from the CONVINCE Clinical TrialDuring this webinar, our speaker and hosts explored the following topics:Study d...
We are proud to announce the publication of our latest research article titled "A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey." This article summarizes the findings of the AwareNASH ...
Last Friday, the results of the CONVINCE trial were published in the prestigious New England Journal of Medicine. We are thrilled to announce that the CONVINCE study has shown that the use of high-dose hemodiafiltration led to a remarkable 23% low...
On the 19th of September, we presented the 9th webinar of our NASH Webinar Series. During this webinar, speaker Professor Zelber-Sagi explored the relationship between diet and NAFLD, emphasizing that diet not only causes NAFLD but can also serve ...
"*" indicates required fields
"*" indicates required fields
